(Q34256126)

31 July 2017

title

The resistance mechanisms of proteasome inhibitor bortezomib (English)

1 reference

31 July 2017

Shuqing Lü

1

1 reference

31 July 2017

Jianmin Wang

series ordinal

2

1 reference

31 July 2017

publication date

1 March 2013

1 reference

31 July 2017

1 reference

31 July 2017

volume

1

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

13

1 reference

Creative Commons Attribution 2.0 Generic

31 July 2017

copyright license

start time

1 March 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Molecular mechanisms of acquired proteasome inhibitor resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Molecular mechanisms of bortezomib resistant adenocarcinoma cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Mechanisms of proteasome inhibitor action and resistance in cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Proteasome inhibition as a novel therapeutic target in human cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

The development of proteasome inhibitors as anticancer drugs

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

The structure of the mammalian 20S proteasome at 2.75 A resolution

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

The 26S proteasome: a molecular machine designed for controlled proteolysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

Anti-angiogenic and anti-tumor properties of proteasome inhibitors

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Molecular mechanisms of proteasome assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177604

IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma

28 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib*

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2050-7771-1-13

CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity

21 January 2018

1 reference

12 December 2020

Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown

1 reference

12 December 2020

Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation

1 reference

12 December 2020

Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen

1 reference

12 December 2020

The multicatalytic proteinase. Multiple proteolytic activities

1 reference

12 December 2020

Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance

1 reference

12 December 2020

Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors

1 reference

12 December 2020

Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma

1 reference

12 December 2020

Identifiers

DOI

10.1186/2050-7771-1-13

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference